Effects of a Mediterranean Eating Plan on the Need for Glucose-Lowering Medications in Participants With Type 2 Diabetes: A Subgroup Analysis of the PREDIMED Trial
Year: 2019
Type: article
Abstract: OBJECTIVE To examine the effects of two Mediterranean eating plans (Med-EatPlans) versus a low-fat eating plan on the need for glucose-lowering medications. RESEARCH DESIGN AND METHODS From the Prevención con Dieta Mediterránea (PREDIMED) trial, we selected 3,230 participants with type 2 diabetes at baseline. These participants were randomly assigned to one of three eating plans: Med-EatPlan supplemented with extra-virgin olive oil (EVOO), Med-EatPlan supplemented with mixed nuts, or a low-fat eating plan (control). In a subgroup (15%), the allocation was done in small clusters instead of using individual randomization, and the clustering effect was taken into account in the statistical analysis. In multivariable time-to-event survival models, we assessed two outcomes: 1) introduction of the first glucose-lowering medication (oral or injectable) among participants on lifestyle management at enrollment and 2) insulin initiation. RESULTS After a median follow-up of 3.2 years, in multivariable analyses adjusting for baseline characteristics and propensity scores, the hazard ratios (HRs) of starting a first glucose-lowering medication were 0.78 (95% CI 0.62–0.98) for Med-EatPlan + EVOO and 0.89 (0.71–1.12) for Med-EatPlan + nuts, compared with the control eating plan. After a median follow-up of 5.1 years, the adjusted HRs of starting insulin treatment were 0.87 (0.68–1.11) for Med-EatPlan + EVOO and 0.89 (0.69–1.14) for Med-EatPlan + nuts compared with the control eating plan. CONCLUSIONS Among participants with type 2 diabetes, a Med-EatPlan + EVOO may delay the introduction of new-onset glucose-lowering medications. The Med-EatPlan did not result in a significantly lower need for insulin.
Source: Diabetes Care
DOI: 10.2337/dc18-2475
Authors: F. Javier Basterra-Gortari, Miguel Ruiz-Canela, Miguel A. Martínez-González, Nancy Babio, José V. Sorlí, Montserrat Fito, Emilio Ros, Enrique Gómez-Gracia, Miquel Fiol, José Lapetra, Ramón Estruch, Luis Serra-Majem, Xavier Pinto, José I. González, Mónica Bulló, Olga Castañer, Ángel Alonso-Gómez, Luis Forga, Fernando Arós
Institutions: Hospital Universitario Reina Sofía, Universidad de Navarra, Instituto de Salud Carlos III, Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition, Centro de Investigación Biomédica en Red, Harvard University, Institut de Recerca Biomèdica Catalunya Sud, Universitat Rovira i Virgili, Universitat de València, Hospital Del Mar, Hospital del Mar Research Institute, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona, Universidad de Málaga, Hospital Universitario Son Espases, Universitat de les Illes Balears, Universidad de Las Palmas de Gran Canaria, Bellvitge University Hospital, Institut d'Investigació Biomédica de Bellvitge, Hospital Universitario Araba, Complejo Hospitalario de Navarra, Navarre Institute of Health Research, University of the Basque Country
Language: English
Topic: Nutritional Studies and Diet
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Abbott Laboratories, Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Alexion Pharmaceuticals, Danone, Amarin Corporation, Kowa Company, Mylan, California Walnut Commission, Generalitat Valenciana, ERAB: The European Foundation for Alcohol Research, Junta de Andalucía, Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición, Grupo Ferrer Internacional, S.A, Fundación Cerveza y Salud, National Institutes of Health, Instituto de Salud Carlos III, European Regional Development Fund, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, NIH Clinical Center
Awards: G1565413406, G1644185098, G1881394406, G1940426220, G2235982870, G2398160727, G247774864, G2580699549, G2620658983, G2647692628, G2860824219, G2996186621, G316735455, G3561316913, G3930416461, G4159188393, G4437166959, G4487147551, G4494103574, G4494622388, G4654025265, G4786509053, G4827889431, G5542193060, G6538752652, G6591504236, G669311712, G6695954693, G6724429843, G7140016538, G7283614615, Dietary Interventions, Metabolites, and Risk of Type 2 Diabetes, G8243675280, G8426496700, Mediterranean diet, Metabolites, and Cardiovascular Disease
OpenAlex ID: W2949083167
